StockData
SCYNEXIS Inc logo

SCYNEXIS Inc (SCYX) stock

SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3072% below fair value
$2.85−0.06 (-2.06%)

Close on Nov 17, 2026Market cap $28.36MP/E –Yield –

Earnings

Scynexis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2022
$1.60M
+220.0% on a year earlier
EPS, Q3 FY2022
-$0.62
-$0.06 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Scynexis's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2023ended Dec 31, 2023Mar 28, 2024during market hours–––Release
Q3 FY2022ended Sep 30, 2022Nov 9, 2022before the open$1.60M+220.0%-$0.62Release
Q2 FY2022ended Jun 30, 2022Aug 15, 2022before the open$1.30M–$0.31Release
Q1 FY2022ended Mar 31, 2022May 12, 2022during market hours$700.00K–-$0.17Release
Q4 FY2021ended Dec 31, 2021Mar 29, 2022before the open$600.00K–-$1.05Release
Q3 FY2021ended Sep 30, 2021Nov 10, 2021before the open$500.00K–-$0.06Release
Q4 FY2017ended Dec 31, 2017Mar 5, 2018during market hours–––Filing
Q3 FY2016ended Sep 30, 2016Oct 5, 2016during market hours–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Scynexis has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Scynexis puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Scynexis filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?